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AntiretroviralAntiretroviral therapy can inhibit HIV replication in patients and prevent progression to AIDS. However, it
is not curative. Here we provide an overview of what antiretroviral drugs do and how the virus persists
during therapy in rare reservoirs, such as latently infected CD4+ T cells. We also outline several innova-
tive methods that are currently under development to eradicate HIV from infected individuals. These
strategies include gene therapy approaches intended to create an HIV-resistant immune system, and acti-
vation/elimination approaches directed towards ﬂushing out latent virus. This latter approach could
involve the use of novel chemically synthesized analogs of natural activating agents.
 2013 Elsevier Ltd. All rights reserved.Beginning with its ﬁrst transmission into humans from chim-
panzees approximately 100 years ago,1 human immunodeﬁciency
virus (HIV) has had a devastating effect throughout the world. At
the end of 2011 an estimated 34 million people were living with
HIV, and in that year approximately 1.7 million people died of ac-
quired immunodeﬁciency syndrome (AIDS).2 There is currently no
vaccine to prevent HIV infection, and while efforts to develop such
a prophylactic vaccine are beginning to show promise,3 it is a com-
plex challenge which is unlikely to be achieved in the near future.
Signiﬁcant advances for treating HIV have been made in the area of
antiviral therapy. However, these treatments are expensive and
can result in side-effects, adherence issues, and the development
of drug-resistant virus. Most importantly, they are not curative,
and must instead be taken for the remainder of the patient’s life
to effectively contain the virus and prevent progression to AIDS.
Furthermore, access to such drugs is limited for individuals in
many parts of the world.2 Developing a cure for HIV to eliminate
the virus from people who are already infected is therefore an
important area of research. The purpose of this review is to de-
scribe what currently available HIV therapies do, outline our
understanding of why they do not cure the infection, and discuss
several novel approaches that are currently under development
for eliminating HIV from infected individuals.HIV infects and kills cells of the immune system, including
CD4+ T cells and macrophages.4 These cells are critical for mount-
ing effective immune responses against invading pathogens. Over
time, HIV replication causes depletion of these cells, leading to
lower total CD4+ T cell numbers, damage to the architecture of
lymph nodes and other lymphoid tissues, immune activation, and
general dysregulation of immune function.4 After an average infec-
tion time of around 10 years, the immune system is damaged to
the point that the infected individual progresses to AIDS. At this
stage the individual becomes highly susceptible to both common
and unusual infections and cancers, which ultimately result in
death.4
Since HIV replication is required for the development of disease,
antiretroviral drugs have been developed to prevent this replica-
tion and stop progression to AIDS.5 A diagram outlining the major
steps in the HIV life cycle and the targets of clinically approved
antiretroviral drugs is shown (Fig. 1). As a retrovirus, the genetic
material in HIV virions (virus particles) is RNA, but the virus repli-
cates through a DNA intermediate that is integrated into the DNA
of the host cell. During infection, the virus ﬁrst binds to the CD4
protein and a coreceptor protein at the cell surface. The most com-
monly utilized coreceptors are the chemokine receptors CCR5 and
CXCR4, with CCR5 usage generally predominating in early infec-
tion, and often maintained throughout infection.6 The viral and
host cell membranes then fuse, and the virion-borne reverse trans-
criptase enzyme catalyzes conversion of the viral RNA into DNA.
This DNA is transported into the nucleus as part of a pre-integra-
tion complex. The viral integrase enzyme then mediates the inte-
gration process, whereby the viral DNA is inserted into the host
Figure 1. Essential steps in the HIV life cycle and targets of currently available antiretroviral drugs. (1) HIV virus particles (virions) bind to CD4 and a coreceptor (generally
CCR5 or CXCR4) on target cells. (2) The viral envelope proteins mediate fusion of the viral and host cell membranes, allowing the viral RNA to be released into the host cell
cytoplasm. (3) The viral RNA is reverse transcribed into double stranded DNA by the HIV reverse transcriptase enzyme. (4) Double stranded viral DNA is translocated into the
nucleus and the HIV integrase enzyme catalyzes integration of this DNA into the host cell’s chromosomes. At this point the HIV genome is referred to as ‘proviral DNA’ or an
‘integrated provirus’. (5) Transcription of the HIV genome is mediated by host cell polymerases. (6) and (7) HIV RNA is exported to the cytoplasm for translation or
incorporation into new virions. For expression of some proteins, the RNA is spliced prior to nuclear export. (8) and (9) New virions assemble and bud from the plasma
membrane. (10) As virions bud, the viral protease enzyme cleaves HIV polyproteins into individual subunits, producing infectious, mature virions. Underscored steps
represent those that are targeted by clinically-approved antiretroviral drugs.
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manently integrated and will be maintained for the lifespan of the
host cell. HIV RNA is then transcribed from the integrated provirus,
and is either translated into proteins (following RNA splicing for
certain viral proteins), or directly incorporated into new virions.
The virions assemble and bud from the plasma membrane. Finally,
the viral protease enzyme cleaves polyproteins within the virion to
produce mature infectious virus particles that are ready to infect a
new cell.
Over 20 antiretroviral drugs have been approved for use in HIV
infected patients.5 These drugs variously inhibit virus entry (fu-
sion/entry inhibitors), reverse transcription (reverse transcriptase
inhibitors), integration (integrase inhibitors), or maturation (prote-
ase inhibitors) (Fig. 1). Modern antiretroviral therapy regimes typ-
ically consist of speciﬁc combinations of three antiretroviral drugs
termed combination antiretroviral therapy (cART) or highly active
antiretroviral therapy (HAART). The rationale behind using multi-
ple drugs with non-overlapping resistance proﬁles is to increase
the suppression of virus replication achieved by the therapy while
also reducing the likelihood of the virus becoming resistant to the
drugs. Importantly, these antiretroviral drugs only inhibit virus
replication. Therefore they can stop the virus from spreading to
new cells but have no direct effect on an integrated HIV provirus.
Untreated HIV infection is generally characterized by a contin-
uous battle between the virus and the host immune response, with
billions of new virions and infected cells produced and cleared
every day (Fig. 2).7 The fact that the adaptive immune responsemaintains much of its function for years during this onslaught is
a testament to its strength and regenerative capacity. Treatment
with HAART eliminates the vast majority of (or potentially all)
HIV replication, and plasma viral loads often fall to levels that
are undetectable with standard clinical assays (such assay limits
are typically 50 copies of virion RNA/ml of plasma).4 However, cer-
tain reservoirs of replication-competent virus persist during ther-
apy. Therefore if HAART is stopped then virus can emerge from
these reservoirs and rapidly spread,8 causing renewed progression
towards AIDS. The resultant rebound in plasma viral loads typically
occurs within several weeks of stopping therapy, indicating that
virus is being released from reservoirs with regularity.9
The best understood reservoir of HIV during HAART consists of
latently-infected CD4+ T cells. These cells are resting (primarily
central and transitional memory) CD4+ T cells that harbor an inte-
grated HIV provirus and express little or no viral RNA and no viral
proteins, but can be induced to produce infectious virus if the cell
becomes activated.10–13 In this non-expressing state the latent pro-
virus cannot be recognized by the immune system, and conse-
quently the infected cell is not eliminated by immune effector
mechanisms. Latently-infected CD4+ T cells are relatively rare in
HAART-treated patients, with approximately 1 latently-infected
cell per million total resting CD4+ T cells, translating into about
one million latently-infected cells per patient.14 These memory
CD4+ T cells are a key component of immunological memory re-
sponses, and it is believed that they can survive for decades even
while harboring latent HIV proviruses. The stability of this reser-
Figure 2. Suppression of HIV replication during therapy. The natural course of HIV infection is associated with extremely high levels of virus replication. Treatment with
highly active antiretroviral therapy (HAART) inhibits the vast majority of this replication, but HIV persists at low levels in very rare cellular reservoirs in these individuals. If
HAART is stopped for any reason, the virus can emerge from these reservoirs, allowing replication to continue at pre-therapy levels.
M. D. Marsden, J. A. Zack / Bioorg. Med. Chem. Lett. 23 (2013) 4003–4010 4005voir during HAART is formidable. It has been estimated that deple-
tion of the latent reservoir using HAART alone would take over 70
years.15
Studies of latently-infected cells from infected individuals as
well as in vitro experiments using both cell lines and primary
CD4+ cells have provided insights into how latency can be estab-
lished (Fig. 3).16,17 Resting CD4+ T cells cannot be efﬁciently in-
fected by HIV, with incoming virus facing multiple blocks to
infection. The most pronounced block is a reduced efﬁciency of re-
verse transcription.18 However, if the cell is activated, it then be-
comes susceptible to productive infection by HIV. This activation
generally happens when the cell encounters an antigen-presenting
cell displaying a foreign peptide that the T cell recognizes, resulting
in signaling through its T cell receptor. Partial activation with cyto-
kines can also shift the cell from a G0 resting phenotype into a state
that can support HIV infection.19 The majority of activated T cells
that are infected by HIV will die, but a small subset of activated
T cells naturally transition into resting memory cells. This transi-
tion is associated with a reduction in cellular transcriptional activ-
ity and a variety of other changes that together are capable of
preventing expression of HIV. Thus if an infected cell undergoes
this transition before it can be killed by the virus or the immune
response, then it can become a latently-infected cell harboring a
non-expressing HIV provirus. If the cell subsequently becomes
activated, for example by recognition of its cognate antigen or
exposure to a proinﬂammatory cytokine environment, then newinfectious virus can be produced. Additional mechanisms for estab-
lishment of latency may also contribute to the pool of latently-in-
fected cells observed in vivo, such as rare direct infection of resting
CD4+ T cells,20 or infection during certain stages of T cell develop-
ment (thymopoiesis).21
In addition to CD4+ T cells, other cell types such as hematopoi-
etic stem cells22 and monocyte/macrophage cells23 might also be-
come latently-infected. However, the regularity in which this
occurs and the contribution of these cell types to persistence of
HIV over the course of many years of therapy is unclear. Macro-
phages can also become chronically infected in some cases, where-
by they continuously produce low levels of virus over extended
periods of time without being killed by the virus.24 There is also
evidence that HAART does not prevent all HIV replication in some
individuals. Ongoing virus replication due to incomplete HAART
suppression in these individuals would clearly provide a source
of HIV to seed viral rebound upon cessation of therapy. Therefore,
the latent reservoir in CD4+ T cells might not be the only source of
replication-competent HIV that persists during HAART. In spite of
this possibility, latently-infected CD4+ T cells are a major focus
of HIV cure research because this reservoir is the only one that
has been convincingly demonstrated to be capable of maintaining
replication-competent HIV over many years of effective
HAART.15,25 Hence, even if other reservoirs are also present, the la-
tent reservoir still represents a key barrier to eradication that will
need to be surmounted before a cure for HIV is achieved.
Figure 3. Generation of HIV latency. (A) Resting CD4+ T cells cannot generally support HIV replication. (B) However, if the cells are stimulated by cytokines or recognition of
their cognate antigen then they become activated and susceptible to HIV infection. Infection will generally result in death of the host cell, but a small subset of these cells will
transition back to a resting state before they can be killed by the virus. (C) The result is a shut-down of HIV expression and production of a long-lived latently-infected cell that
harbors an HIV provirus that is not producing viral proteins. (D) Subsequent activation of this latently infected cell (perhaps many years later) results in re-initiation of virus
expression and production of new infectious virions.
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investigated. Most of these can be broadly categorized as gene
therapy/transplantation approaches that are generally intended
to protect cells of the immune system from HIV infection, and acti-
vation/elimination approaches directed towards ﬂushing out the
latent virus. These methodologies are not necessarily mutually
exclusive, but each is intended to either cure the infection by elim-
inating all replication competent virus from the individual, or pro-
duce a ‘functional cure’ whereby the levels of HIV are substantially
reduced in a durable manner without ongoing therapy, such that
disease progression does not occur and transmission of virus to
new hosts is highly unlikely.
The idea of using allogeneic (non-self) transplants to cure HIV is
supported by a remarkable single case which has galvanized the
ﬁeld.26,27 This individual, sometimes referred to as the ‘Berlin Pa-
tient’, was HIV-positive with suppressed viral loads through effec-
tive HAART. He then developed a life-threatening acute myeloid
leukemia. Treatment for the leukemia involved the use of extre-
mely aggressive chemotherapy to eliminate the cancerous cells,
which also depleted the majority of his HIV host cells (CD4+ T cells
and macrophages). He then received two bone marrow transplants
to provide CD34+ hematopoietic stem cells that could differentiate
into new blood cells. Matched donor cells were identiﬁed that were
homozygous for a CCR5 delta-32 mutation. This is a naturally-
occurring mutation that results in cells which cannot express the
CCR5 HIV coreceptor, but because of overlapping functionality
and redundancy in the immune signaling network, it does not ap-
pear to affect the health of individuals carrying it. Approximately
1% of Caucasians are homozygous for this mutation, and are there-
fore naturally resistant to infection by the CCR5-tropic strains of
HIV that generally predominate in most infected individuals.6 Dur-
ing the transplant process the patient stopped HAART, and HIV vir-
al loads did not increase. Testing of blood and tissues over the
subsequent 4 years has failed to ﬁnd evidence for replicating
HIV. It therefore appears that in this particular case, the combina-
tion of chemotherapy to deplete endogenous HIV host cells fol-
lowed by repopulation with HIV-resistant cells was sufﬁcient to
clear the infection. Additional contributing factors such as graftversus host disease, which occurred during the course of treat-
ment, could also have contributed towards the elimination of
pre-existing cellular reservoirs of virus.26 This case is tentatively
being hailed as the ﬁrst instance of an individual being cured of
HIV.27
However, there are numerous reasons that this approach cannot
be extended to all infected individuals. The aggressive chemother-
apy alone carries signiﬁcant risks. In addition, locating an appropri-
ate bone marrow donor match that is also CCR5 delta-32
homozygous is not possible for many individuals, and use of
imperfectly-matched allogeneic donor cells can result in problems
associated with immune incompatibilities. Finally, the expense and
complexity of the process require well-funded and sophisticated
medical facilities that are not available for most people infected
with HIV. Nevertheless, this case has provided a proof-of-concept
that HIV can be cured. Therefore alternative approaches based on
similar principles are being developed that could be more broadly
applied.
Several gene therapy approaches for treating HIV are under
investigation. These are generally directed towards introducing
an anti-HIV gene of some type into cells obtained from the in-
fected patient, then reinfusing these cells back into the same pa-
tient. The use of autologous cells from the same patient should
reduce or eliminate the problems with immunological incompat-
ibility that are characteristic of allogeneic cell transfers. The
genes could be introduced into differentiated peripheral cells
such as CD4+ T cells. However, most of these cells do not persist
for long periods of time in vivo. Therefore an alternative
approach is to introduce the therapeutic gene into CD34+ hema-
topoietic stem cells (Fig. 4), which are capable of self-renewal,
can differentiate into all blood cell types, and are theoretically
able to produce differentiated cells expressing the anti-HIV genes
indeﬁnitely.28 Under ideal circumstances, such cells would be
refractory to HIV infection and would thus be able to maintain
an effective immune response and prevent progression to AIDS.
A diverse armamentarium of anti-HIV approaches have been
developed and tested for gene therapy applications.29–31 These in-
clude antisense RNAs, short peptides, intrabodies, short-hairpin
Figure 4. Gene therapy approaches for eliminating HIV. Therapeutic genes can be introduced into CD34+ hematopoietic stem cells. As these cells differentiate, the introduced
genes will also be present and expressed in progeny cells. In this way CD4+ T cells can be produced that are resistant to HIV infection or encode genes for anti-HIV factors.
Examples shown here include: genes encoding T cell receptors against HIV, that could be used to produce cytotoxic T lymphocytes that target HIV-infected cells; genes
encoding short-hairpin RNAs (shRNAs) and ribozymes, that can cleave viral RNA or the RNA for the CCR5 receptor for HIV, making the cell resistant to infection; genes
encoding recombinases or homing endonucleases, that can inactivate integrated HIV DNA, and various RNAs and proteins that can interfere with HIV protein functions.
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ﬁnger nucleases and ribozymes. Some of these gene-based thera-
peutics directly target HIV proteins or RNA to prevent productive
infection altogether or to reduce the amount of virus expression
in an infected cell. For example shRNAs are capable of causing
mRNA degradation and inhibition of protein translation in a se-
quence-speciﬁc manner. Therefore shRNAs have been designed
that target mRNA regions across the HIV genome, including coding
sequences for the essential HIV regulatory proteins Tat and Rev,
accessory proteins such as Nef, and the major open reading frames
encoding the structural (Gag), polymerase (Pol), and envelope
(Env) proteins.32 The HIV Rev protein is required for exporting par-
tially spliced and unspliced HIV transcripts from the nucleus. Early
studies have shown that the function of this protein can be dis-
rupted by expression of a dominant negative version of Rev, and
this fact has been exploited in exploratory gene therapy ap-
proaches.33,34 HIV Tat protein is critical for producing high levels
of HIV transcription. Both Tat and Rev function by binding to spe-
ciﬁc RNA secondary structures on the HIV genome, termed the
transactivation response element (TAR) and Rev response element
(RRE), respectively. RNA decoys that resemble these natural struc-
tures have been produced, which bind to the viral proteins and
interfere with their function.35,36 A ribozyme (catalytic RNA) that
sequence-speciﬁcally cleaves HIV RNA has also been developed
and tested through Phase I and Phase II clinical trials.37 Moreover,
a membrane-anchored peptide termed C46 has also been shown to
prevent fusion of the viral and host cell membranes when ex-
pressed in potential HIV host cells, by binding to and inhibiting
the gp41 region of HIV Env.38Given that latent HIV consists of an integrated provirus that is
not directly affected by antiviral drugs, several interesting methods
to inactivate such non-expressing proviruses are also under inves-
tigation. One method involves introducing a gene encoding for an
evolved recombinase that is capable of excising the integrated pro-
virus.39 A second involves the use of homing endonucleases that
can cleave the proviral DNA, leading to disruption of its coding se-
quence following DNA repair by the host cell.40
Gene-based strategies that affect cellular proteins are also un-
der investigation. One such approach involves knock-down or
knock-out of CCR5 to protect the host cells from infection by
CCR5-tropic HIV variants and hopefully achieve similar results
to those observed with the Berlin Patient. Successful methods
for reducing levels of CCR5 expression in cells have included
the use of shRNA41,42 and ribozyme43 technologies that speciﬁ-
cally target CCR5 mRNA. Another promising approach for elimi-
nating CCR5 expression is the use of zinc ﬁnger nucleases44 that
can irreversibly inactivate the CCR5 gene following transient
expression in hematopoietic stem cells, and thus do not require
a therapeutic gene to be permanently maintained in the cells.
This CCR5-speciﬁc zinc ﬁnger nuclease approach has been suc-
cessfully applied to a humanized mouse model of HIV
infection.45
Utilizing a combination of genes with different mechanisms of
action would probably provide better protection to the cells than
use of a single protective gene, and it would also make selection
of resistant virus less likely. To this end, combinatorial gene ther-
apy approaches are being developed. For example, a recent clinical
trial involved the introduction of a vector encoding a TAR decoy
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ome and an anti-CCR5 ribozyme.46
Another way that gene therapy may be utilized in treating HIV
infection is via the introduction of genes that generate more effec-
tive immune responses against the virus. One example of this is the
introduction of an HIV-speciﬁc T cell receptor, which results in the
production of cytotoxic T lymphocytes that can target and kill cells
expressing particular HIV proteins.31
As with the development of all new therapeutics, safety consid-
erations are of paramount importance. To date, the majority of
clinical studies using gene therapy for HIV treatment have been fo-
cused on determining the safety and feasibility of the procedures
rather than optimizing efﬁcacy. These trials have demonstrated
that stem cell-based gene-transfer clinical trials can be conducted
safely with a relatively large number of study participants (in one
case, 74 HIV-infected individuals37). Challenges that these trials
have highlighted are currently being addressed, including the need
to increase the frequency of cells harboring the newly-introduced
transgene in vivo. Further limitations to current gene therapy ap-
proaches include the expense and complexity of the procedures,
the potential for long-term complications associated with intro-
duction of foreign genes into cells (e.g., insertional mutagenesis
or off-target DNA damage), and side effects of chemotherapy that
may be required to deplete some endogenous cells in order to
‘make space’ for the newly-introduced cells. Nevertheless, if opti-
mized, these gene therapy approaches would offer the possibility
for HIV-infected individuals to receive a single treatment, or collec-
tion of treatments, that would provide lifelong protection against
development of AIDS without the continual need for antiretroviral
drugs.
The second major strategy for purging latently-infected cells is
often referred to as an ‘activation/elimination’ approach (Fig. 5).
The goal of this strategy is to ﬂush out the latent virus by inducing
it to express viral proteins. If high levels of HIV expression are gen-
erated then the cell may be killed by the damaging effects of virus
production itself (viral cytopathic effects) or apoptosis. Once pro-
teins are expressed, the infected cell should also become visible
to the immune system and can be targeted by effector cells such
as CD8+ cytotoxic T lymphocytes or other therapeutic agents direc-
ted towards viral proteins. In order to prevent the activated virus
from initiating new rounds of virus replication, activation/elimina-
tion approaches would be performed during continuous HAART.
Early clinical attempts to purge latent virus in vivo relied on
stimulation of T cells with the cytokine interleukin (IL)-2. A signif-
icant effect on latently-infected cell numbers was identiﬁed in
these studies, but viral rebound was still observed following cessa-
tion of antiretroviral therapy.8,9,47 Administration of IL-2 in con-
junction with an anti-CD3 monoclonal antibody that stimulates T
cells through the T cell receptor was also attempted, but the treat-
ment was associated with toxic side-effects.48 These important
exploratory studies demonstrated that the ‘blunt force’ approach
of inducing global T cell activation would not be sufﬁcient to
achieve the goal of HIV eradication. Consequently more selective
methods based on our growing understanding of latency have been
investigated. Though a detailed description of the molecular mech-
anisms underlying HIV latency and strategies for activating latent
virus is provided elsewhere,16,17 examples of several areas of cur-
rent interest are outlined below.
Protein kinase C (PKC) activators such prostratin, a non-tumor-
inducing phorbol ester, and bryostatin 1, a marine macrolide, can
induce HIV from latency via activation of the transcription factor
NF-jB.17 Bryostatin 1 has been tested in over 30 clinical trials as
a cancer therapeutic, but isolation from natural sources is expen-
sive and problematic. In collaboration with theWender lab at Stan-
ford University, we recently described the synthesis of bryostatin
analogs that are inexpensive to produce and display improvedHIV latency activation properties in a cell line model49 (e.g.,
Fig. 6A). The Wender laboratory has also succeeded in synthesizing
analogues of prostratin.50 The in vivo safety and efﬁcacy of these
new compounds has yet to be determined, but since these analogs
can in principle be tuned for performance, there is now greater lat-
itude for optimization during preclinical testing.
Histone deacetylases (HDACs) can produce hypoacetylated
nucleosomes at the HIV promoter, which reduces access of tran-
scription factors and contributes to the maintenance of HIV la-
tency. Conversely, HDAC inhibitors can induce latent HIV
expression. One such compound termed ‘vorinostat’ (suberoylani-
lide hydroxamic acid, Fig. 6B), is already approved for clinical use
for cancer applications. Initial results from a recent clinical trial
using vorinostat to activate HIV from latency have shown that it
can increase HIV transcription in resting CD4+ T cells from
HAART-treated patients, demonstrating that the latent reservoir
can be perturbed in vivo using HDAC inhibitors.51 Additional HDAC
inhibitors including romidepsin, panobinostat and others have also
shown promise as HIV latency activating compounds and are cur-
rently being further studied.
Moreover, HDAC inhibitors and PKC activators have also been
found to induce HIV from latency in a synergistic manner. There-
fore combinations of different latency activators may prove more
effective than either one individually.
In addition, a variety of other mechanisms may contribute to la-
tency, such as the actions of histone methyltransferases, DNA
methyltransferases, bromodomain proteins, and the lack of posi-
tive transcription elongation factor b (pTEFb) in latently-infected
cells. Hence, compounds that affect these factors are also under
investigation.17 For example the transcriptional regulator bromod-
omain containing 4 (BRD4) competes with HIV Tat for pTEFb,
thereby reducing HIV transcription and potentially contributing
to maintenance of HIV latency.52 Consistent with this concept,
the BRD4 inhibitor JQ1 (Fig. 6C) has been shown to be capable of
activating HIV from latency.52,53 Consequently this and other sim-
ilar bromodomain inhibitors54 may prove useful in HIV eradication
efforts.
Since expression of HIV is closely associated with the activation
state of the host cell, there is concern that the most effective la-
tency-activating agents may cause generalized immune activation,
for example via induction of abundant proinﬂammatory cytokines
(sometimes referred to as a cytokine storm). This has the potential
to be directly toxic to the patient, and it also would create a large
number of activated T cells at the time of latency induction, mak-
ing virus spread to these potential new host cells more difﬁcult to
contain with HAART. One potential approach for enhancing efﬁ-
cacy while reducing off target effects is to direct the latency acti-
vating compounds more selectively to the cell type of interest.
For example, we recently described the use of lipid nanoparticles
for introducing bryostatin 2 speciﬁcally to CD4+ cells.55 Further-
more, the copackaging of the HIV protease inhibitor nelﬁnavir into
these particles allowed the same particle to simultaneously acti-
vate HIV from latency while inactivating any virions released from
the cell.
There is also some evidence that activation of the virus from la-
tency may not be sufﬁcient to kill the cell, particularly if only a
small amount of virus expression is induced.56 Hence, additional
interventions such as therapeutic vaccination to enhance anti-
HIV immune responses, use of genetically modiﬁed HIV-speciﬁc
cytotoxic T lymphocytes (Fig. 4), or immunotoxins that can bind
to and kill cells expressing HIV Env on the surface (Fig. 5) may
prove useful in killing the recently activated latently-infected
cells.57 Furthermore, our understanding of HIV latency has focused
primarily on the 2–3% of T cells that are circulating in the periph-
eral blood, and we have limited information regarding how la-
tently-infected cells residing in tissues will respond to potential
Figure 5. Activation/elimination approaches to purge the latent HIV reservoir. (A) A variety of different stimuli have been shown to be capable of inducing a latent HIV
provirus to express new viral proteins. In some cases combinations of inducers (such as PKC activators and HDAC inhibitors) can act synergistically in this process. (B) Once
virus expression has been activated in the latently-infected cell, HIV spread to new cells will be inhibited by the continued presence of HAART. The host cell may be killed
directly by cytopathic effects associated with virus replication. Alternatively, the cell could be killed by immune effector mechanisms or novel therapeutic approaches
targeted towards viral proteins. HDAC (histone deacetylase), HMT (histone methyltransferase), PKC (protein kinase C), IL (interleukin).
Figure 6. Examples of HIV latency activating compounds currently under investigation. (A) Bryostatin analog (PKC activator). (B) Vorinostat (HDAC inhibitor). (C) (+)-JQ1
(bromodomain inhibitor).
M. D. Marsden, J. A. Zack / Bioorg. Med. Chem. Lett. 23 (2013) 4003–4010 4009therapies. The use of relevant small animal models may allow a
more thorough investigation of this important question.58,59
Eliminating HIV from infected individuals is a complex prob-
lem. However, there is increasing optimism within the ﬁeld thatcuring HIV is an achievable goal. Some of the approaches that are
under investigation are expensive, labor intensive, and compli-
cated. If a cure is developed then the next challenge will be to
make it available to infected individuals throughout the world,
4010 M. D. Marsden, J. A. Zack / Bioorg. Med. Chem. Lett. 23 (2013) 4003–4010including those who currently have no access to available HIV
therapies.
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